Group items tagged

The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.

The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.   

This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy).  For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA. 

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

This NIH Funding Opportunity Announcement (FOA) is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program. This FOA solicits applications for support of research to gather critical data and answer critical questions on functional peripheral neuroanatomy of organs and reveal the organ function controlled by neural circuits.   Organs of interest include those where the peripheral neuroanatomy and functional neurobiology of the organ have been understudied, and which are not the subject of existing SPARC funding under RFA-RM-15-018 (see below).  

This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain cancers, and high risk leukemias.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers. The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this FOA) must be focused on cancers of the breast, prostate and other genitourinary organs, and lung. In addition, cancers with rapidly rising incidenc

Leidos will match high-scoring, unfunded National Institutes of Health (NIH) proposals with private biomedical foundations and/or industries seeking to fund promising research. Foundations will have access to peer-reviewed research proposals that directly relate to their funding priorities, industry will have access to a rich pipeline of early stage and translational research proposals that align with its priorities, while applicants with strong research proposals will be provided with a second opportunity to secure funding. The foundations, industries, applicants, and NIH all will benefit from this synergy.

The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Applications requesting more than 15% overhead are usually not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation. A final report summarizing financial expenditure and research achievement is required.

The Education Committee solicits proposals for funding visits of toxicologists to developing nations to expand awareness of toxicology and promote toxicology careers through interaction of toxicologists with undergraduate and graduate students. Up to $1250 funding is available per request. The Education Committee encourages the applicant to seek matching funding from partners, whether a SOT Special Interest Group, employer, or host institution. A letter from the contact at the institution to be visited is required and letters from sponsoring partner(s) would be included as part of the application.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to support small grants in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for, primary immunodeficiency diseases. The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA.

The Process and Reaction Engineering program supports fundamental and applied research on: Rates and mechanisms of important classes of catalyzed and uncatalyzed chemical reactions as they relate to the design, production, and application of catalysts, chemical processes, biochemical processes, and specialized materials Chemical and biochemical phenomena occurring at or near solid surfaces and interfaces Electrochemical and photochemical processes of engineering significance or with commercial potential Design and optimization of complex chemical and biochemical processes Dynamic modeling and control of process systems and individual process units Reactive processing of polymers, ceramics, and thin films Interactions between chemical reactions and transport processes in reactive systems, and the use of this information in the design of complex chemical and biochemical reactors  Recent emphasis on the development of sustainable energy technologies means that the support of projects on the processing aspects of chemical systems that further such technologies have high priority when funding decisions are made. Areas that focus on reactors of all types - fuel cells, batteries, microreactors, biochemical reactors, etc.; reactor design in general; and design and control of all systems associated with energy from renewable sources, have high priority for funding.

Due to the ubiquitous presence of catalysis in the many aspects of goods and services impacting our lives, the Catalysis and Biocatalysis program has many potential directions for funding support.  Programs in this area encompass a blend of fundamental and innovative applied research drivers.  All programs are hypothesis-driven, and the experimental programs aimed at resolving the issues frequently combine a variety of approaches.  Chemical engineering and chemistry are intertwined.  Proposals which receive funding in this Program may include any number of the following broad scopes: Catalyst Synthesis, Characterization, Behavior and Performance Kinetics and Mechanisms of Key Catalytic Reactions Catalysis at Surfaces or in Reactor Process Streams Synthesis and Fabrication of Component Materials and Catalyst Composites Modeling and Fundamental Studies of a Catalyst or Catalytic Process Catalysts and Studies for Renewable Energy Systems. These approaches apply equally to classical inorganic or carbon catalysts as well as to enzymatic or biocatalysts.  Specialized materials synthesis procedures may be necessary to provide active catalysts in any of the studies.  Applications-driven studies, such as Biomass conversion catalysis, Electrocatalysis and Photocatalysis, involving energy interconversion devices or systems employing catalysts are highly desired.

The Directorate for Biological Sciences (BIO) awards Postdoctoral Research Fellowships in Biology to recent recipients of the doctoral degree for research and training in selected areas supported by BIO and with special goals for human resource development in biology.  The fellowships encourage independence at an early stage of the research career to permit Fellows to pursue their research and training goals in the most appropriate research locations regardless of the availability of funding for the Fellows at that site.  For FY 2013, these BIO programs are (1) Broadening Participation in Biology; (2) Intersections of Biology and Mathematical and Physical Sciences and Engineering; (3) National Plant Genome Initiative Postdoctoral Research Fellowships; and (4) International Postdoctoral Research Fellowships in Biology.  These areas change periodically as new scientific and infrastructure opportunities present themselves. For this reason, this solicitation will be changed as necessary to reflect the areas being funded.

Mentored Research Training Grants help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators. The MRTG is a two-year, $175,000 award that provides funding to faculty members who have completed their core anesthesiology residency training within the past 10 years. Year one is funded up to $75,000, and year two is funded up to $100,000. The MRTG requires 75 percent protected non-clinical time for research. The proposed project must be in basic science, clinical or translational, or health services research. Mentored Research Training Grant - Basic Science Studies pertaining to any of the fundamental questions broadly related to anesthesiology. Typically laboratory experiments with cells or animals.

The purpose of this Funding Opportunity Announcement (FOA) is to establish a Model Organisms Screening Center for evaluating the pathogenicity and function of approximately 200 gene variants per year identified through the Undiagnosed Diseases Network (UDN). Responsive applications will propose to establish a screening platform involving at a minimum Drosophila and zebrafish models; the screening pipeline may include additional small animal models or cell-based assays, as appropriate, to analyze the function of UDN gene variants in the context of the respective UDN patient's disease phenotype. This initiative is funded through the NIH Common Fund which supports cross-cutting programs that are expected to have exceptionally high impact.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit revisions (competitive supplements) to add a Big Data Science track to currently funded T32 institutional training grants for the expressed purpose of training the next generation of scientists who will develop computational and quantitative approaches and tools needed by the biomedical research community to work with biomedical Big Data in the biomedical sciences (see definition under Funding Opportunity Description). This proposed training initiative should prepare qualified individuals for careers in developing new technologies and methods that will allow biomedical researchers to maximize the value of the growing volume and complexity of biomedical data.

JDRF is launching an initiative to overcome challenges for increased longevity for delivery of insulin via sub-cutaneous infusion. Components include infusion sets and cannula used in patch pumps. Based on these EOIs, potential applications will be subsequently invited to be developed and submitted as full proposal. In this call, JDRF intends to fund innovative approaches to identifying the fundamental mechanism of failure and/or provide mitigations to known failure modes when delivering insulin via sub-cutaneous cannula. The immediate aim is to increase the reliability of insulin infusion, with an ultimate aim to extend the wear duration of infusion sets and patch pumps to match the wear duration of CGMs, for the majority of people with T1D. The objective of this initiative is to identify common mechanisms of failure, or demonstrate effective mitigation of known failure mechanisms, in continuous sub-cutaneous insulin infusion. Examples of mechanisms of failure discovery may include, but are not limited to: * ECM or other protein deposition * Inflammation and wound healing process * Fibrosis * Tissue Granulation Examples of mitigations for known failure modes may include: * Drug eluting materials * Cannula Coatings or Surface treatments * Insulin Excipients Discovery proposals must have a clear pathway to commercial viability, and particular emphasis will be given to novel mechanisms of mitigation. Evaluations of proposed mitigations will require preliminary evidence of an underlying mechanism to be addressed. MECHANISM Successful EOIs from for profit entities would be invited under our Industry Development and Discovery Program mechanism1. Applications from nonprofit organizations, public and private universities, colleges, hospitals, laboratories, units of state and local governments would be invited under our Strategic Research Agreement mechanism2. Projects should request costs commen

The Society for Pediatric Dermatology (SPD) announces a call for proposals to compete for four research grants supporting the field of pediatric dermatology. The William Weston Research Award (funding up to $20,000) supports scholarly clinical or basic research. Proposals are evaluated on their importance to pediatric dermatology, their scientific merit and their likelihood of success. Preference is given to young investigators seeking to establish a research program and to members of the Society. One (1) Weston Research Award will be given in 2015. The Pilot Project Award (funding up to $7,500) supports the initiation of studies important to Pediatric Dermatology. Preference is given to clinical studies and to projects by SPD members. Collaborative clinical studies are encouraged. Recipients of Pilot Project Award are eligible to apply for the William Weston Research Award in subsequent funding cycles. Three (3) Pilot Project Awards will be given in 2015.

The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but often still require significant progress before they can apply to governmental or industrial funding agencies. Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards are meant to fund projects in an established laboratory that will serve as the basis for the applicant's own independent research career.